In Advance Of Pharma Partnership, Intarcia Inks Equity Deal With Quintiles

The CRO will conduct Phase III trials on an implantable device that delivers exenatide to Type 2 diabetes patients, while an anticipated pharma partner will help commercialize it around the world.